Familial hypercholesterolemia in Mexico: Initial insights from the national registry.

Background: Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated.

Objective: Report the results of the first years (2017-2019) of the Mexican FH registry.

Methods: There are 60 investigators, representing 28 federal states, participating in the registry.

A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America.

Patients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent atherosclerotic cardiovascular disease (CVD) events. Dyslipidaemia, a major risk factor for CVD, is poorly controlled post ACS in countries outside Western Europe and North America, despite the availability of effective lipid-modifying therapies (LMTs) and guidelines governing their use. Recent guideline updates recommend that low-density lipoprotein cholesterol (LDL-C), the primary target for dyslipidaemia therapy, be reduced by ≥ 50% and to < 1.

Third national registry of acute coronary syndromes (RENASICA III).

Objective: RENASICA III is a prospective, multicenter registry on acute coronary syndromes (ACS). The main objective will be to identify the outcome in tertiary and community hospitals and perform strategies to improve quality of care in Mexico.

Methods: RENASICA III will enroll 8000 patients in public health and private hospitals.

Primary reperfusion in acute right ventricular infarction: An observational study.

Aim: To investigate the impact of primary reperfusion therapy (RT) on early and late mortality in acute right ventricular infarction (RVI).

Methods: RVI patients (n = 679) were prospectively classified as without right ventricular failure (RVF) (class A, n = 425, 64%), with RVF (class B, n = 158, 24%) or with cardiogenic shock (CS) (class C, n = 96, 12%). Of the 679 patients, 148 (21.

Risk factors, therapeutic approaches, and in-hospital outcomes in Mexicans with ST-elevation acute myocardial infarction: the RENASICA II multicenter registry.

Background: Ischemic heart disease is a growing health problem in Latin America. We aimed to analyze risk factors, acute management, and short-term outcome of Mexicans with ST-elevation myocardial infarction (STEMI).

Hypothesis: Modifiable risk factors are associated with the occurrence of STEMI in Mexicans, and potentially preventable acute complications are responsible for most short-term deaths.

Patients with hypertensive crises who are admitted to a coronary care unit: clinical characteristics and outcomes.

Patients with hypertensive crises, especially hypertensive emergencies, require immediate admittance to an intensive care unit for rapid blood pressure (BP) control. The authors analyzed the prevalence of hypertensive crisis, the clinical characteristics, and the evolution of patients with hypertensive emergencies and urgencies. Patients were divided into 3 groups according to their BP values: group I, predominant systolic hypertension (≥180/≤119 mm Hg); group II, severe systolic and diastolic hypertension (≥180/≥120 mm Hg); and group III, predominant diastolic hypertension (≤179/≥120 mm Hg).

The TIMI risk score for STEMI predicts in-hospital mortality and adverse events in patients without cardiogenic shock undergoing primary angioplasty.

Introduction: Patients with ST elevation acute myocardial infarction (STEMI) comprise a heterogeneous population with respect to the risk for adverse events. Primary percutaneous coronary intervention (PCI) has shown to be better, mainly in high-risk patients.

Objective: The purpose of this study was to determine if the Thrombolysis in Myocardial Infarction (TIMI) risk score for STEMI applied to patients undergo primary PCI identifies a group of patients at high risk for adverse events.

[Hemorrhagic complications of acute coronary syndromes treatment].

Acute coronary syndromes represent a problem of public health. The main goal of the treatment includes early reperfusion and avoidance of recurrent ischemic events. For this, thrombolytic, anticoagulant and antiplatelet drugs are used and, although they clearly improve the ischemic prognosis, are also associated with bleeding.

[Clinical characteristics and treatment of ventricular septum rupture after acute myocardial infarction].

Objective: To identify the characteristics, management strategy and mortality of patients with acute myocardial infarction (AMI) and rupture of ventricular septum (RVS).

Methods: The study included 40 patients admitted during a period of 8 years, due to AMI complicated with RVS. RVS was confirmed by echocardiogram.

In-hospital outcome in patients with ST elevation myocardial infarction and right bundle branch block. A sub-study from RENASICA II, a national multicenter registry.

Objective: Compare in-hospital outcome in patients with ST-elevation myocardial infarction with right versus left bundle branch block.

Methods: RENASICA II, a national Mexican registry enrolled 8098 patients with final diagnosis of acute coronary syndrome secondary to ischemic heart disease. In 4555 STEMI patients, 545 had bundle branch block, 318 (58.

A proposed functional clinical classification predicts in-hospital and long-term survival in the setting of acute right ventricular infarction.

Background: The objectives of the present investigation were to validate the prognostic role of a proposed Clinical Classification [CC], to evaluate the TIMI risk score [RS] and to establish whether the TIMI-RS should incorporate points for patients with acute right ventricular infarction [TIMI-RS-RVI].

Methods And Results: A total of 523 RVI patients were classified on clinical and functional basis as: A, without right ventricular failure [RVF], B with RVF and C with cardiogenic shock. The CC was evaluated prospectively among 98 patients with RVI and retrospectively in 425 RVI patients.

[ST elevation acute coronary syndromes. Pharmaco-mechanic strategy is the universal treatment future?].

The main objective in the medical treatment of the ST elevation acute myocardial infarction, must have the intention to reperfuse the culprit involved artery. In order to reduce this time, the pharmaco-invasive strategy may offer rapid flow recanalization in the culprit artery and reduce the damage of the myocardium. The new pharmacologic combinations includes half dose of fibrinolytics, alone or in combination with IIb/IIIa inhibitors, this combination may offer advantages of the flow.

[Mortality in cardiogenic shock].

Objective: Cardiogenic shock (CS) is one of principal causes of mortality after an acute myocardial infarction (MI). The objective of this study was to determine the principal causes that contribute to an increase in mortality in CS.

Methods: We studied 155 consecutive patients with CS admitted to the Coronary Care Unit of the Instituto Nacional de Cardiologia Ignacio Chávez from 1990-2002.

[Troponins and the indication for treatment with IIb/IIa inhibitors in acute coronary syndromes without ST-segment elevation. Is it time for an "INR" value of troponins?].

At the present time non-ST elevation acute coronary syndromes are the most important cause of hospital admissions. Troponin determination in clinical practice is a key element of diagnosis, risk evaluation and prognosis, and now, defines the population that will benefit from IIb/IIIa inhibitors treatment. Probably a "universal standard value of Troponins" is needed to uniform our therapeutic criteria.

[The target of reperfusion in acute coronary ischemic syndrome with ST segment elevation. The major paradigm: "Beyond TIMI 3 flow: the TIMI 4 or myocardial tissue-level perfusion"].

Treatment for ST- elevation acute coronary syndromes (acute myocardial infarction: AMI) has advanced rapidly in the last decade with major improvements in early fibrinolytic therapy (FT), primary percutaneous interventions (PCI) with the aid of platelet glycoprotein IIb/IIIa inhibitors. Recent interest has shifted from infarct related artery (IRA) patency to microvascular perfusion in the evaluation of patients with AMI. It is well known that establishing epicardial patency after AMI (TIMI 3 E) is not synonymous with tissue-level perfusion (TIMI 4M).

[Decrease of total hemorrhage with reduced doses of enoxaparin in high risk unstable angina. ENHNFAI study. (Enoxaparin vs non-fractionated heparin in unstable angina). Preliminary report].

Unlabelled: In this prospective, randomized and controlled study, we compare complications in 2 groups of patients: group 1, enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days, and group 2, intravenous unfractionated heparin during 5 days, by infusion treated to activate partial tromboplastin time 1.5-2 the upper limit of normal.

[Rational treatment of hypertensive crises].

The Hypertensive Crisis can be divided into Emergencies and Urgencies. Hypertension may be unknown at presentation. The Emergencies have acute or ongoing end-organ damage (neurological, renal or cardiovascular).

Acute right ventricular infarction: clinical spectrum, results of reperfusion therapy and short-term prognosis.

Background: The role of thrombolytic therapy (TT) and percutaneous coronary interventions (PCIs) in subgroups of patients with right ventricular infarction (RVI) has not been evaluated.

Methods And Results: We risk-stratified 302 patients with RVI into three subsets upon admission. Class A (n=197) comprised patients without right ventricular (RV) failure, Class B (n=69) with RV failure and Class C (n=36) with cardiogenic shock.